הכנסה תפעולית לפני ניכוי פחת: Avadel Pharmaceuticals PLC (AVDL)

סמל מסחרי של Avadel Pharmaceuticals plc (AVDL)

Risks for Avadel Pharmaceuticals (AVDL) are tied to patents and the adoption rate of Lumryz. However, the business relies on the macro-resilience of the sector, where demand remains independent of crises. The absolute EBITDA trend confirms this stability, with its latest reading standing at 8.19. Growth is supported by partnerships with specialized sleep clinics to optimize narcolepsy therapy.

רווח תפעולי EBITDA Avadel Pharmaceuticals (AVDL): לתקופה 23.11.2025 - 28.02.2026

פילוחי נתונים אנליטיים מרוכזים עבור Avadel Pharmaceuticals plc (AVDL)

- מחיר מניה וקונצנזוס הערכת שווי:
אנליטיקה מסכמת של החברה:AVDL (Avadel Corp)
פריט של המותג Avadel Pharmaceuticals

This indicator serves as a fundamental tool for assessing the asset's operational efficiency, capturing daily earnings before interest and taxes to reflect actual cash flow. By analyzing changes in EBITDA_Co, an investor can identify hidden demand trends prior to official reports. For Avadel Pharmaceuticals (AVDL), this metric confirms the commercial viability of its proprietary sleep medications. A stable chart indicates high capitalization of unique developments within the US market.